Completed PHASE3 INTERVENTIONAL NCT00328978

Seroquel STACK Study in Schizophrenic or Schizoaffective Subjects

A Canadian, Multicenter, Double-Blind, Randomized, Parallel-Group Study of the Safety, Tolerability, and Efficacy of Treatment With Higher Doses of Quetiapine Fumarate (Seroquel®) Greater Than 800 mg/Day in Schizophrenic or Schizoaffective Subjects.

Sponsor: AstraZeneca

Conditions Schizoaffective Disorders Schizophrenia

Interventions Quetiapine

Updated 6 times since 2017 Last updated: Mar 24, 2009 Started: Oct 31, 2003 Completion: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Schizoaffective Disorders and Schizophrenia, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 6 data snapshots since 2003. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Calgary, Canada , Edmonton, Canada , Kingston, Canada , London, Canada , Markham, Canada , Mississauga, Canada , Montreal, Canada , Ottawa, Canada , Québec, Canada , Saskatoon, Canada and 7 more locations